Fig. 15: Impact of TTR point mutations and ligand binding.

RMSD of V50M in apo form and bound to tafamidis or acoramidis, showing rescue of wild-type-like flexibility.
RMSD of V50M in apo form and bound to tafamidis or acoramidis, showing rescue of wild-type-like flexibility.